Zimmer Biomet Holdings CapEx decreased by 51.5% to $36.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 18.6%, from $44.60M to $36.30M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 11.8% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $24.60M | $44.00M | $49.20M | $36.40M | $40.90M | $47.20M | $63.40M | $46.70M | $97.30M | $84.30M | $62.80M | $55.10M | $52.70M | $44.50M | $51.50M | $44.60M | $50.10M | $55.00M | $74.80M | $36.30M |
| QoQ Change | — | +78.9% | +11.8% | -26.0% | +12.4% | +15.4% | +34.3% | -26.3% | +108.4% | -13.4% | -25.5% | -12.3% | -4.4% | -15.6% | +15.7% | -13.4% | +12.3% | +9.8% | +36.0% | -51.5% |
| YoY Change | — | — | — | — | +66.3% | +7.3% | +28.9% | +28.3% | +137.9% | +78.6% | -0.9% | +18.0% | -45.8% | -47.2% | -18.0% | -19.1% | -4.9% | +23.6% | +45.2% | -18.6% |